52 Vanderbilt Avenue Suite 1510 New York, NY 10017-3834

tel 212.969.9800 • fax 212.969.9822 • toll free 888.654.ICRF (4273)

e-mail info@icrfonline.org • web site www.icrfonline.org

# POLICIES GOVERNING THE BEVERLEY LIBRACH ABSHEZ INITIATIVE FOR OVARIAN AND FEMALE REPRODUCTIVE SYSTEM CANCERS

The Israel Cancer Research Fund (ICRF) is a voluntary charitable organization that receives its total income from private donations. The goal of the ICRF is to advance cancer research and the training of Israeli scientists in Israel.

ICRF grants awarded under this special initiative will provide funding for projects of high scientific merit and clear potential significance for advancing the understanding, diagnosis and/or treatment of ovarian and female reproductive system cancers. Grant support will be awarded only to investigators who are Israeli citizens, and the research supported must be conducted at an Israeli institution.

#### **Purpose**

Cancer that starts in a woman's reproductive organs is called gynecologic cancer. The five main types of gynecologic cancer are: cervical, ovarian, uterine, vaginal, and vulvar. (A sixth type is the very rare fallopian tube cancer.) Of all the gynecologic cancers, only cervical cancer has screening tests that can find this cancer early, when treatment can be most effective. Ovarian cancer ranks fifth in cancer deaths among women, accounting for more deaths than any other cancer of the female reproductive system. Each gynecologic cancer is unique, with different signs and symptoms, different risk factors, and different prevention strategies. All women are at risk for gynecologic cancers, and the risk increases with age. For these reasons, determining risk factors (genetic, environmental and gene-environment interactions), developing preventive strategies, improving detection technologies, and devising new strategies for targeted treatment of gynecologic cancers are very important goals for cancer research.

The ICRF has always been committed to supporting world-class cancer research that contributes to improved cancer treatment and can lead to cancer cures. Graciously sponsored by an anonymous donor, The Beverley Librach Abshez Initiative for Ovarian and Female Reproductive System Cancers has been established to advance our knowledge of the pathogenesis and treatment of gynecologic cancers.

## **Eligibility**

These special grants are intended to support the research of established investigators working in areas in which they have demonstrated expertise. Applications will only be considered from individuals who have completed at least three years of postdoctoral fellowship training (or the equivalent) on the date on which the grant is activated. The grant is made to an institution with the understanding that it will support a specific project under the direction of a designated principal investigator. Multi-investigator applications and interdisciplinary approaches are encouraged, but not required. However, applicants are required to provide strong published or preliminary data in support of the proposed research.

### **Duration and Amount of the Grant**

These special grants will be awarded for three (3) years for \$100,000 per year, as determined by the Scientific Review Panel and the availability of funds. It is anticipated that two (2) grants will be awarded. Funding for the second and third years is contingent on progress in the preceding funding period, as documented in a progress report due annually on June 30.

ICRF 1/2 ABSHEZ INITIATIVE POLICIES

# **Further Information**

Additional information and templates for applying for an ICRF cancer research grant can be downloaded from our website, <a href="www.icrfonline.org/apply-for-a-grant/">www.icrfonline.org/apply-for-a-grant/</a>.

For information on **General Policies Governing ICRF Grants**, including fiscal requirements for sponsoring institutions, please see the following pages.

Questions? For any questions or problems, please send an E-mail message to: ellen.rubin@icrfny.org